Contact Points
Gardner, MA 01440
This notice of proposed acquisition is posted as an intent to award a purchase order on a non-competitive basis to New England Peptide, Inc.
This acquisition is restricted to New England Peptide, Inc. because New England Peptide, Inc. is the only one who can provide experimental continuity for custom peptide synthesis.
The National Institute on Aging, Laboratory of Clinical Investigation uses MS-based SRM method has become a leading proteomic technique for the identification of aging biomarkers and therapeutic intervention targets. The SRM assay has advantages over ELISA assays that rely upon the recognition of large epitopes because SRM can distinguish variants and isoforms of proteins that cannot be recognized by antibodies. Custom-synthesized peptides are needed for identifying targets with optimal charge state, declustering potential, collision energy and collision cell exit potential. In addition, these synthesized peptides are spiked into human skeletal muscle tissue to serve as internal references, permitting the generation of external concentration response curves.
The Laboratory of Clinical Investigation requires 2 mgs of high purified custom synthesis peptides with stable isotopic labeling.
Item Names and Quantity:
LI 1 220NLRP3 H2N-YLEDLEDVDLK^-OH 11 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No K^ = Lysine (13C6,15N2)
LI 2 222NLRP3 H2N-DVTVLLENYGK^-OH 11 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No K^ = Lysine (13C6,15N2)
LI 3 224NLRP3 H2N-NPQ(Cam)NLQK^-OH 8 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No (Cam) = Cys-CAM (carbamidomethylation), K^ = Lysine (13C6,15N2)
LI 4 228Pax7 H2N-TGFPLEVSTPLGQGR^-OH 15 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No R^ = Arginine (13C6,15N4)
LI 5 230Pax7 H2N-VSHG(Cam)VSK^-OH 8 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No (Cam) = Cys-CAM (carbamidomethylation), K^ = Lysine (13C6,15N2)
LI 6 232Pax7 H2N-STVPSGLVSSISR^-OH 13 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No R^ = Arginine (13C6,15N4)
LI 7 234Pax7 H2N-NVSLSTQR^-OH 8 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No R^ = Arginine (13C6,15N4)
LI 8 236MyH3&8 H2N-LASADIETYLLEK^-OH 13 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No K^ = Lysine (13C6,15N2)
LI 9 238MyH3&8 H2N-EQDTSAHLER^-OH 10 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No R^ = Arginine (13C6,15N4)
LI 10 240MyH3&8 H2N-LLASIDIDHTQYK^-OH 13 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No K^ = Lysine (13C6,15N2)
LI 11 242PML H2N-APASEEEFQFLR^-OH 12 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No R^ = Arginine (13C6,15N4)
LI 12 244PML H2N-(Cam)DISAEIQQR^-OH 10 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No (Cam) = Cys-CAM (carbamidomethylation), R^ = Arginine (13C6,15N4)
LI 13 246PML H2N-(Cam)SQTQ(Cam)PR^-OH 8 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No (Cam) = Cys-CAM (carbamidomethylation), R^ = Arginine (13C6,15N4)
LI 14 248PML H2N-LWGPGLPNFFR^-OH 11 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No R^ = Arginine (13C6,15N4)
LI 15 250P53 H2N-LGFLHSGTAK^-OH 10 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No K^ = Lysine (13C6,15N2)
LI 16 252P53 H2N-(Cam)SDSDGLAPPQHLIR^-OH 15 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No (Cam) = Cys-CAM (carbamidomethylation), R^ = Arginine (13C6,15N4)
LI 17 254P53 H2N-ELNEALELK^-OH 9 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No K^ = Lysine (13C6,15N2)
LI 18 256Gal1 H2N-DSNNL(Cam)LHFNPR^-OH 12 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No (Cam) = Cys-CAM (carbamidomethylation), R^ = Arginine (13C6,15N4)
LI 19 258Gal1 H2N-FNAHGDANTIV(Cam)NSK^-OH 15 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No (Cam) = Cys-CAM (carbamidomethylation), K^ = Lysine (13C6,15N2)
LI 20 260Gal1 H2N-LPDGYEFK^-OH 8 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No K^ = Lysine (13C6,15N2)
LI 21 262SMP30 H2N-GLIHALDPGTGQETAR^-OH 16 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No R^ = Arginine (13C6,15N4)
LI 22 264SMP30 H2N-IEASSPHLR^-OH 9 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No R^ = Arginine (13C6,15N4)
LI 23 266SMP30 H2N- LSASGPLDGAVLK^-OH 14 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No K^ = Lysine (13C6,15N2)
LI 24 268PTBP1 H2N-TDSSPNQAR^-OH 9 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No R^ = Arginine (13C6,15N4)
LI 25 270PTBP1 H2N-HQNVQLPR^-OH 8 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No R^ = Arginine (13C6,15N4)
LI 26 272PTBP1 H2N-VLFSSNGGVVK^-OH 11 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No K^ = Lysine (13C6,15N2)
LI 27 274Exoc7 H2N-LENSIIPVHK^-OH 10 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No K^ = Lysine (13C6,15N2)
LI 28 276Exoc7 H2N-HLSEALNDK^-OH 9 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No K^ = Lysine (13C6,15N2)
LI 29 278Exoc7 H2N-AWAIPDTEQR^-OH 10 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No R^ = Arginine (13C6,15N4)
LI 30 280GRSF1 H2N-GLQTGPVPPGR^-OH 11 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No R^ = Arginine (13C6,15N4)
LI 31 282GRSF1 H2N-NGENGIHFLLNR^-OH 12 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No R^ = Arginine (13C6,15N4)
LI 32 284GRSF1 H2N-SSPVVNDGVVR^-OH 11 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No R^ = Arginine (13C6,15N4)
LI 33 286ZSCAN4 H2N-EEGISEFSR^-OH 9 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No R^ = Arginine (13C6,15N4)
LI 34 288ZSCAN4 H2N-DVIVHLTK^-OH 8 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No K^ = Lysine (13C6,15N2)
LI 35 290ZSCAN4 H2N-GFFQISDLR^-OH 9 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No R^ = Arginine (13C6,15N4)
LI 36 292VGF H2N-LLQQGLAQVEAGR^-OH 13 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No R^ = Arginine (13C6,15N4)
LI 37 294VGF H2N-HYHHALPPSR^-OH 10 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No R^ = Arginine (13C6,15N4)
LI 38 296VGF H2N-AQEEAEAEER^-OH 10 residues >95% Purity 2mgs Amino Acid Analysis (AAA) - No R^ = Arginine (13C6,15N4)
Contract Type:
A Firm Fixed Price type order award not exceeding the Simplified Acquisition Threshold is anticipated to be awarded resulting from this requirement.
Summary Statement:
The Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response.
All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.”
Quoter Terms and Conditions (To be completed by the Offeror):
1. Period of Performance OR Delivery Date After Receipt of Order:
2. Shipping Point (F.O.B. OR Destination):
3. Payment Discount Terms:
4. NIH BPA Number, if applicable:
5. DUNS No:
6. Name of Company:
7. Street Address, City, State, Zip code:
8. Name of Person Authorized to Provide Quote:
9. Telephone Number and Email Address of Person Authorized to Provide Quote:
The following provisions and clauses apply to this acquisition and are incorporated as an attachment. Offerors MUST complete the provision at 52.204-24 and 52.204-26 and submit completed copies as separate documents with their quotation.
1. FAR 52.204-24, Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment (Aug 2020)
2. FAR 52.204-25, Prohibition on Contracting for Certain Telecommunications and Video Surveillance Services or Equipment (Aug 2020)
3. FAR 52.204-26, Covered Telecommunications Equipment or Services-Representation (Oct 2020)
Acquisition Authority: This acquisition is being conducted under Federal Acquisition Regulations (FAR) Part 13 – Simplified Acquisition Procedures, and the resultant contract award will include all applicable provisions and clauses in effect through Federal Acquisition Circular 2021-05 published in the Federal Register on March 10, 2021.
All responses must be received by April 12, 2021 by 12:00 pm EST and must reference announcement / solicitation number. NIA21-005836MD. Responses may be submitted electronically to malita.dyson@nih.gov. Fax responses will not be accepted.
All responsible sources may submit response which, if timely received, must be considered by the agency.
Interested parties may identify in writing their interest and capability in response to this requirement. Responses to this notice shall contain sufficient information to establish the interested parties’ bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.
All responses must be received by closing date and must reference the announcement. Responses may be submitted electronically to the attention of the contract specialist. Fax responses will not be accepted.
All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency.